Biodiscovery LLC

Biodiscovery LLC, doing business as Daicel Arbor Biosciences, is a foreign-owned manufacturer of custom molecular biology and genomic research reagents that operates as a prime contractor delivering specialized DNA sequencing kits, MYBAITS custom target capture reagents, and cell-free protein expression products to federal biomedical research and forensic agencies. The vendor competes in full-and-open (non-set-aside) procurements and is a subsidiary of Chiral Technologies Inc., a foreign-owned for-profit manufacturer based in West Chester, Pennsylvania.

Biodiscovery's customer footprint concentrates sharply on the Defense Health Agency, which accounts for 30 awards worth $14.2 million in combined potential value—88% of the vendor's total portfolio across 21 distinct federal customer agencies. The next-largest customers by award count, the Smithsonian Institution (23 awards, $247 thousand) and the Department of the Army Medical Command (8 awards, $1.1 million), generate significantly smaller dollar value and volume; the concentration by dollars is even more extreme, with DHA alone representing 97% of the vendor's combined potential value. This customer concentration reflects Biodiscovery's role as the exclusive supplier of MYBAITS proprietary reagents under DHA's single-award $5.3 million Blanket Purchase Agreement (W81XWH22A0005), which runs through September 27, 2027 and has generated 17 task orders worth $2.8 million. Secondary BPA vehicles include a second DHA agreement (W81XWH17A0009) with 12 task orders for $2.2 million. Representative capability work under the primary DHA BPA spans custom target enrichment kits ($185 thousand, January 2026; $275 thousand, February 2025; $215 thousand, March 2026), MYBAITS reagents for casework analysis ($414 thousand, June 2023; $609 thousand, May 2025), and MYBAITS Mito and whole-genome enrichment kits ($169 thousand, February 2025; $27 thousand, March 2024). Outside DHA, Biodiscovery holds smaller purchase orders from the FDA ($35 thousand, May 2026 for KAPA baits), the National Human Genome Research Institute ($13 thousand, January 2025 for degraded DNA extraction), the National Institute of Allergy and Infectious Diseases ($25 thousand, August 2024 for custom Trypanosomes kits), the CDC ($14 thousand, September 2023 for MYBAITS reagents), the Smithsonian Institution (recurring orders ranging $5 thousand to $70 thousand for DNA sequencing and scientific supplies), the Department of Agriculture's Forest Service ($37 thousand, July 2023 for target capture and sequencing of Coleoptera and Hemiptera samples), and USDA's Midwest Area ($20 thousand, December 2024 for biotinylated RNA-based bait enrichment for citrus and sugar beet research).

Biodiscovery's award portfolio spans 94 federal prime contracts and IDVs with a combined potential value of $16.2 million, of which $9 million is obligated (56% fulfillment rate). Activity has averaged 7 to 9 awards per year from 2022 through 2025, with 2026 showing three awards to date. The vendor carries minimal recompete risk—only one award worth $35 thousand reaches ultimate completion within the next twenty-four months. The portfolio breaks into specialized NAICS categories: Research and Development in the Physical, Engineering, and Life Sciences (22 awards), Analytical Laboratory Instrument Manufacturing (18 awards), In-Vitro Diagnostic Substance Manufacturing (17 awards), Testing Laboratories and Services (8 awards), and Research and Development in Biotechnology (8 awards). By PSC code, Laboratory Equipment and Supplies accounts for 36 awards; Support Professional Services for 11; In-Vitro Diagnostic Substances, Reagents, Test Kits and Sets for 10. Performance occurs at Biodiscovery's manufacturing facility in Ann Arbor, Michigan, with all work conducted on a firm fixed-price basis and no small business set-aside designations across the portfolio.